Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025